Showing results (271-280 of 340) with videos related to
Sort By:
Pageof 34
Circulation|October 20, 2004
Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuriaFolkert W Asselbergs, Gilles F H Diercks, Hans L Hillege, et al.Circulation|February 8, 2006
Renal function as a predictor of outcome in a broad spectrum of patients with heart failureHans L Hillege, Dorothea Nitsch, Marc A Pfeffer, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|August 30, 2011
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trialEdmund J Lewis, Julia B Lewis, Tom Greene, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 19, 2003
The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysisTazeen H Jafar, Christopher H Schmid, Paul C Stark, et al.Journal of the American Society of Nephrology : JASN|December 8, 2004
Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interactionRichard P E van Dokkum, Wouter B A Eijkelkamp, Alex C A Kluppel, et al.The New England Journal of Medicine|November 6, 2012
Cardiorenal end points in a trial of aliskiren for type 2 diabetesHans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.Journal of the American Society of Nephrology : JASN|October 29, 2011
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathyDavid K Packham, Rory Wolfe, Anne T Reutens, et al.Cardiovascular Research|April 7, 2021
Effects of canagliflozin on myocardial infarction: a post hoc analysis of the CANVAS programme and CREDENCE trialJie Yu, Jingwei Li, Phillip J Leaver, et al.Clinical Journal of the American Society of Nephrology : CJASN|August 21, 2007
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL studyWilliam F Keane, Zhongxin Zhang, Paulette A Lyle, et al.Diabetes, Obesity & Metabolism|May 5, 2026
Effects of Vicadrostat/Empagliflozin in People With Chronic Kidney Disease: Metabolic Subgroup AnalysesDavid Z I Cherney, Peter Rossing, Maria Eugenia Canziani, et al.Pageof 34